摘要
目的观察米力农联合西地兰治疗慢性心力衰竭(CHF)的疗效,探寻一种时效性高及疗效可靠的CHF治疗方案。方法选择心功能Ⅲ~Ⅳ级慢性心力衰竭患者,参考患者意愿及某类基础病情分成西地兰组32例、米力农组28例、联合用药组40例,记录患者N末端原脑利钠肽(NT-pro BNP)、有无疗效、住院期间心力衰竭发生率、药物副作用发生率,以心功能Ⅱ级为出院标准给予出院,记录住院天数、住院总费用和日均费用。结果 (1)各组间治疗有效率差异无统计学意义(P>0.05);(2)米力农组住院期间心力衰竭发生率大于西地兰组及联合用药组(P<0.05);(3)西地兰组洋地黄中毒发生率大于联合用药组(P<0.05);(4)住院天数及住院总费用按米力农组、西地兰组及联合用药组依次递减(P<0.05)。结论短期使用米力农治疗失代偿期CHF安全、有效,其联合西地兰能显著减少洋地黄中毒发生率,减少住院时间,降低CHF患者的医疗经济负担。
Objective To observe the efficacy of milrinone combined withdigilanid C in the treatment of the chronic heart failure and to explore a treatment program with high timeliness and reliable results. Methods The patients of chronic heart failure with NYHA Ⅲ-Ⅳ were divided into the digilanid C group( 32 cases),the milrinone group( n = 28) and the combined group( n = 40). The NT-pro BNP,the incidence of adverse events and side effects of drugs were recorded. The number of hospital days,the total cost of hospitalization and the average daily cost were recorded,when the patients of chronic heart failure with NYHA Ⅱ were discharged. Results( 1)There was no significant difference in the rate of treatment between the three groups( P > 0. 05).( 2) The incidence of heart failure during the hospitalization of the milrinone group was higher than that of the digilanid C group and the combined group( P < 0. 05).( 3) The incidence of digitalis poisoning in thedigilanid C group was greater than that in the combined group( P < 0. 05).( 4) The total hospitalization days and the total cost of hospitalization were decreased according to the order of the milrinone group,the digilanid C group and the combined group( P < 0. 05). Conclusions The short-term use of milrinone in the treatment of decompensated CHF patients is safe and effective. It can significantly reduce the incidence of digitalis poisoning,hospital stay and the medical burden combined with digilanid C.
出处
《安徽医药》
CAS
2017年第10期1900-1903,共4页
Anhui Medical and Pharmaceutical Journal
关键词
慢性心力衰竭
西地兰
米力农
住院天数
Chronic heart failure
Digilanid C
Milrinone
Hospital days
